Effectiveness of dermatocosmetic products «Psoriaten» in the treatment of chronic allergic dermatoses: results of a clinical study
Authors: Reznichenko Yu.G. , Reznichenko N.Yu. , Gurja O.M. , Onishchenko N.Yu. , Veretelnyk K.O. , Petrashyna O.M. 
Published: December 2024

Objective — to increase the effectiveness of the treatment of patients with chronic allergic dermatoses by using dermatocosmetic products Psoriaten in complex therapy based on the study of skin microbiocenosis, psychological state and quality of life of patients.
Materials and methods. The monitoring involved 107 people, including 72 patients with chronic allergic dermatoses (38 with atopic dermatitis and 34 with true eczema), who were divided into 2 groups: the experimental group — 35 patients who used Psoriaten ointment and dermatocosmetic product Psoriaten along with standard therapy for 6 months; the comparison group — 37 patients who received only standard treatment for 6 months. The control group included 35 healthy people. All patients were examined according to existing standards. We used Biochemical and microbiological methods, evaluation of the expressiveness of chronic allergic dermatoses according to the SCORAD index, determination of the level of anxiety according to the HADS anxiety and Hamilton anxiety scales, neuroticism — according to the H. Eysenck scale, depression — according to the HADS depression hospital scale, Hamilton’s depression scale, assessment of quality of life using the Dermatology Life Quality Index (Ukrainian version of the Dermatology Life Quality Index — DLQI) and CQLS and the integral indicator of the self-assessment questionnaire. The obtained results were processed statistically using standard computer programs.
Results and discussion. 3 months after the start of treatment in the experimental group, a statistically significant decrease in the SCORAD index was noted in patients with allergic dermatitis who additionally used Psoriaten, so after 6 months, a statistically significant difference in DSCORAD (%) was observed at the end of treatment between the experimental and comparison groups. This indicates a positive clinical effect of using dermatocosmetic product Psoriaten in complex chronic allergic dermatoses therapy. The effectiveness of additional use of Psoriaten in the treatment of chronic allergic dermatosis is indicated by the presence of a statistically significant difference after 6 months of therapy between the group that received only standard therapy and the group with additional use of Psoriaten in the total number of bacteria, the number of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis, Streptococcus pyogenes, Candida fungi. After 6 months from the start of treatment, patients in the group that additionally received Psoriaten had statistically significantly lower rates of anxiety, neuroticism, and depression compared to the group that received only standard therapy. The obtained results indicate a significant improvement in the quality of life of patients with chronic allergic dermatoses against the background of the use of Psoriaten and testify to the high effectiveness of its use not only in terms of the regression of clinical manifestations, but also in terms of a significant improvement in the quality of life of patients.
Conclusions. The use of drugs of the Psoriaten group in the treatment of patients with chronic allergic dermatoses for 6 months has a positive effect on the normalization of the skin microbiome and the reduction of general skin insemination, reliably reduces the SCORAD indices, contributes to the reduction of anxiety, neuroticism and depression against the background of improving the clinical manifestations of the disease, which results in an improvement quality of life. The results give a reason to recommend the widespread introduction of Psoriaten products in the complex therapy of patients with chronic allergic dermatoses.